Auven Therapeutics significantly enhances the value of its portfolio of small molecules or biologics through global development programs that clinically and commercially validate these product candidates before selling to established pharmaceutical companies for further development and marketing.
Acquiring Products from Auven Therapeutics
Auven seeks to divest marketable products with appropriate organizations to bring valuable life-saving and life-enhancing therapeutics to the global marketplace.
For further information, Email Us
Benefits of Acquiring Commercial Product Rights from Auven Therapeutics:
- Compound targeting critical unmet medical need with strong commercial potential
- Minimal to no infrastructure attached to the compound
- Flexible deal structure
- Compound with global IP strategy secured
- A substantially de-risked compound at approval stage or with a clear path to approval
- Freedom to market/position the compound to suit buyer’s needs/expertise and current products
- All products are Swiss domiciled for optimal tax planning
- Robust global clinical development program defined or completed
- Carefully considered global registrational strategy in place or completed
- Commercial Manufacturing plan identified or completed